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See Article, pages 64–71Decompensation of cirrhosis, in particular acute-on chronic liver
failure (ACLF), is associated with a systemic inﬂammatory
response that is characterized by high leukocyte counts and high
plasma C-reactive protein levels, and has been correlated with
higher mortality [1]. The triggers of this inﬂammation are
currently unknown. Overt bacterial infection might explain a part
of it, but the association between the severity of decompensation
and systemic inﬂammation is also observed in non-infected
patients. This systemic inﬂammation could be driven by
enhanced translocation of viable intestinal microorganisms to
mesenteric lymph nodes, bacteria-derived products (pathogen
associated molecular patterns, PAMPs), or by mediators, released
by ‘‘sterile’’ injured tissue (damage-associated molecular pat-
terns, DAMPs). Increased bacterial translocation of viable bacteria
and bacterial products is observed and permitted by increased
intestinal permeability, which is partially due to alterations in
tight junction (TJ) proteins in the advanced stages of cirrhosis
[2]. Some PAMPs, such as lipopolysaccharide (LPS) and bacterial
DNA (bactDNA), have been detected in the blood of patients with
decompensated cirrhosis [3].
The innate immune system is the ﬁrst line of defence against
microbial infection and is activated by the engagement of germ-
line-encoded pattern recognition receptors (PRRs) in response to
microbes. PRRs include the membrane-bound Toll-like receptors
(TLRs) and C-type lectins, which scan the extracellular milieu
and endosomal compartments for PAMPs. On one hand, activation
of TLRs on the cell surface results in the release of many cytokines,
including TNF-a, IL-6, and IL-12 [4]. On the other hand, engage-
ment of TLRs induces the production but not secretion of pro-IL-
1b and pro-IL-18. Intracellular PRRs cooperate in a multi-protein
complex, called the inﬂammasome to provide cytosolic surveil-
lance and to activate caspase-1, which proteolytically cleaves
the cytosol-sequestering leader sequence of pro-IL-1b and pro-
IL-18 to generate and release mature cytokines [5]. Membrane
bound and intracellular PRRs cooperate to fully activate IL-1bJournal of Hepatology 20
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Open access under CC BY-NC-ND license.and IL-18 release. Absent inmelanoma 2 (AIM2) has been recently
identiﬁed as a cytosolic double-stranded DNA (dsDNA) sensor,
contributing to the inﬂammasome complex by combining with
ASC and caspase-1 [6]. The ligands of AIM2 are cytosolic dsDNAs,
coming from viruses, bacteria, and the host.
Cirrhosis is classically associated with a systemic inﬂamma-
tion, characterized by enhanced expression of pro-inﬂammatory
cytokines (TNF-a, IL-6, IL-1b, and IL-18) in the serum and in
peripheral blood mononuclear cells, which overproduce ex vivo
pro-inﬂammatory cytokines in response to LPS, the TLR4 ligand
[7–9]. Several mechanisms at least partially explain this overex-
pression. LPS-stimulated monocytes from patients with cirrhosis
display a lack of interleukin-1 receptor-associated kinase (IRAK)-
M induction, decreased Akt activity, defects in glycogen synthase
kinase (GSK)3b phosphorylation, and reduced expression of IL-10,
contributing to the loss of counter-regulatory mechanisms of the
TLR4 pathway and the hyper-production of TNF-a [9–11].
The implications of the inﬂammasome and its dependent cyto-
kine (IL-1b and IL-18) activation in various forms of liver disease,
including liver damage, steatosis, inﬂammation, and ﬁbrosis are
extensively discussed elsewhere [12]. However, the inﬂamma-
some-dependent IL-1b and IL-18 pathways in cirrhosis were
unexplored until publication of the study by Lozano-Ruiz and col-
leagues in the current issue of the Journal of Hepatology [13]. The
authors observed a primed state of ascitic ﬂuid (AF) macrophages
in patients with cirrhosis that was characterized by increased
expression of pro-IL1b and pro-IL18 mRNA, activation of cas-
pase-1, and enhanced expression of AIM2. This pre-activated state
allowed AF macrophages to produce high amounts of mature
IL-1b and IL-18 in response to the AIM2 ligand, dsDNA, without
the requirement of a priming stimulation by extracellular PAMPs.
Moreover, the presence of bactDNA in ascites was associated with
an enhanced AIM2-related pre-activated state, suggesting that
translocation of bactDNA could be responsible for this priming.
This study highlights the compartmentalization of the activation
of innate immune cells in cirrhosis. Compared to AF CD14+ cells,
circulating CD14+ monocytes did not display an AIM2-related
pre-activated state. Detailed study of the activation pattern of
AF leukocytes should offer the interesting future opportunity to
better understand the inﬂammation process in cirrhosis and its
compartmentalization.15 vol. 62 j 11–12
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The AIM2-related pre-activated state of AF macrophages was
also correlated with the severity of cirrhosis. Indeed, IL-1b and
IL-18 production by AF macrophages in response to dsDNA was
enhanced in patients with Child-Pugh C cirrhosis, compared to
those with Child-Pugh B. The authors also observed that higher
production of IL-18 in AF is a Child-Pugh score-independent pre-
dictor of the occurrence of spontaneous bacterial peritonitis. Cas-
pase-1 and IL-18 levels are higher in patients with ACLF
compared to patients with stable chronic liver disease [14]. Taken
together, these data suggest that the inﬂammasome is primed in
advanced cirrhosis and its activation is linked to the severity of
liver disease. At this time, it is difﬁcult to deﬁne whether inﬂam-
masome activation contributes to the progression of cirrhosis and
the occurrence of decompensation or is only a surrogate marker,
associated with the severity of liver disease. The authors suggest
a ‘two-hit’ process for cirrhotic decompensation, in which the ini-
tial activation of AF leukocytes by extracellular PAMPs, e.g. bac-
tDNA, coming from translocation, is followed by activation of a
second inﬂammasome ligand such as DAMPs, e.g. host dsDNA.
Sterile activation of innate immunity in cirrhosis is attractive
but clearly hypothetical at this time. Further translational stud-
ies, with deep assessment of molecular modiﬁcations and detec-
tion of triggers, such as PAMPs and DAMPs, of the innate immune
system in patients with cirrhosis, are clearly needed to suggest
new areas of research and to potentially provide substantial
improvement in outcomes for these patients.Conﬂict of interest
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